BEGIN:VCALENDAR VERSION:2.0 PRODID:-//pretalx//sciencenext.org//ifos2026//MTTHCZ BEGIN:VTIMEZONE TZID:EET BEGIN:STANDARD DTSTART:20001029T030000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10;UNTIL=20061029T000000Z TZNAME:EET TZOFFSETFROM:+0300 TZOFFSETTO:+0200 END:STANDARD BEGIN:STANDARD DTSTART:20071028T050000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10;UNTIL=20141026T020000Z TZNAME:EET TZOFFSETFROM:+0300 TZOFFSETTO:+0200 END:STANDARD BEGIN:STANDARD DTSTART:20151108T050000 RRULE:FREQ=YEARLY;BYDAY=2SU;BYMONTH=11;UNTIL=20151108T020000Z TZNAME:EET TZOFFSETFROM:+0300 TZOFFSETTO:+0200 END:STANDARD BEGIN:STANDARD DTSTART:20160907T010000 RRULE:FREQ=YEARLY;BYDAY=1WE;BYMONTH=9 TZNAME:+03 TZOFFSETFROM:+0300 TZOFFSETTO:+0300 END:STANDARD BEGIN:DAYLIGHT DTSTART:20000326T020000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3;UNTIL=20060326T000000Z TZNAME:EEST TZOFFSETFROM:+0200 TZOFFSETTO:+0300 END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20070325T040000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3;UNTIL=20100328T020000Z TZNAME:EEST TZOFFSETFROM:+0200 TZOFFSETTO:+0300 END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20110328T040000 RRULE:FREQ=YEARLY;BYDAY=4MO;BYMONTH=3;UNTIL=20110328T020000Z TZNAME:EEST TZOFFSETFROM:+0200 TZOFFSETTO:+0300 END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20120325T040000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3;UNTIL=20130331T020000Z TZNAME:EEST TZOFFSETFROM:+0200 TZOFFSETTO:+0300 END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20140331T040000 RRULE:FREQ=YEARLY;BYDAY=5MO;BYMONTH=3;UNTIL=20140331T020000Z TZNAME:EEST TZOFFSETFROM:+0200 TZOFFSETTO:+0300 END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20150329T040000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3;UNTIL=20160327T020000Z TZNAME:EEST TZOFFSETFROM:+0200 TZOFFSETTO:+0300 END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT UID:pretalx-ifos2026-KZBV9Q@sciencenext.org DTSTART;TZID=EET:20260912T114500 DTEND;TZID=EET:20260912T124500 DESCRIPTION:

Head and neck cancer is a common yet aggressive malignancy with a poor prognosis\, particularly w hen diagnosed at advanced stages. Despite progress in surgical\, chemother apeutic\, and radiotherapeutic interventions\, overall disease control and patient survival rates remains low due to high rates of recurrence and th erapeutic resistance. Head and neck cancer continues to be a challenging d isease and many efforts across the world are in process to help diagnose\, treat\, manage and surveil this disease and the patients it affects. Trea tment related toxicity are long lasting and affect patient quality of life and function. Advances in therapeutics and new technologies continue to b e developed and utilized in management of this challenging disease. Neoadj uvant and adjuvant immunotherapy approaches are about to gain approval as standard of care. This may help select patients to de-intensify and if nee ded intensify surgical and non-surgical therapies. Continued advancement a nd study of therapeutic approaches are needed to increase response rates a nd maintain long term control in both HPV positive and negative cancers. A dvances in diagnostics\, treatment\, surveillance and rehabilitation will continue to be needed to improve overall head and neck cancer patient outc omes.

 \;

This panel of experts will discuss new technolog ies\, advances and treatment strategies in head &\; neck cancer. Speake rs and panel discussion will focus on the future of innovation and unmet n eeds\, as well as what is/are the next frontier(s) in head and neck cancer :

 \;

Faculty Roster for American Academy of Otolaryngolog y Panel Symposia:

Wojciech Mydl arz MD

Sidney Kimmel Comprehens ive Cancer Center

Johns Hopkins University School of Medicine

 \;

Clint Allen MD

Center for Cancer Research/National Can cer Institute

National Institut e of Health

 \;

Nicole Schmitt MD

Winship Cancer Institute

Emory University School of Medicine

 \;

Steve n Chinn MD\, MPH

Hillman Cancer Center

University of Pittsburg h Medical Center

 \;

Mark Zafereo MD University of Texas M D Anderson Cancer Center

 \ ;

Jaime Ku MD

Head and Neck Institute

Cleveland Clinic

 \;

Eleni Rettig MD

Brigham and Women's Hospital/Dana -Farber Cancer Institute

Harvar d Medical School

 \;

Melina Windon MD

Markey Cancer Center

University of Kentucky School of Medicine

- Unme t needs in diagnosis\, treatment\, surveillance and rehabilitation of head and neck cancer

- Advances in treatment and response adjusted and directed therapy - Future of clinical trials in head and neck cancer\; next frontier(s)?

- Artificial Intelligence in head and neck cancer

DTSTAMP:20260503T162956Z LOCATION:Head & Neck Surgery 1 SUMMARY:American Academy of Otolaryngology: Future of clinical trials and u nmet needs in Head and Neck Cancer management - Wojciech Mydlarz\, Nicole Schmitt\, Steven Chinn URL:https://sciencenext.org/ifos2026/talk/KZBV9Q/ END:VEVENT END:VCALENDAR